Alopecia areata after dupilumab for atopic dermatitis
نویسندگان
چکیده
AA: alopecia areata AD: atopic dermatitis IL: interleukin Th: T helper INTRODUCTION Dupilumab is the first targeted biologic therapy approved for the treatment of atopic dermatitis (AD). More than 1,000 adult patient exposures formed the basis of its approval in March 2017 for the treatment of moderate-to-severe AD not well controlled with topical therapies or when other therapies are inadvisable. A reassuring safety profile was established, with conjunctivitis being the most significant safety signal.We describe our experience in a patient treated with dupilumab for AD that developed alopecia areata (AA) within 5 weeks of first exposure (3 doses). corticosteroids 7/18/2016e7/26/2016 Cyclosporine Before first appointmente 11/22/2016 Prednisone
منابع مشابه
Cicatricial ectropion in a patient treated with dupilumab
Purpose To describe a case of bilateral conjunctivitis and cicatricial ectropion associated with dupilumab therapy for atopic dermatitis. Observations Severe hyperemia of the conjunctiva and eyelid margins, as well as cicatricial ectropion, began two months after starting weekly dupilumab injections for atopic dermatitis. The findings worsened over the next several months and improved after d...
متن کاملAssociation among Thyroid Dysfunction, Asthma, Allergic Rhinitis and Eczema in Children with Alopecia Areata
BACKGROUND Alopecia areata is a non-scarring hair loss, which typically starts quickly. Atopy is one of the possible predisposing risk factors for this condition. AIM This study aimed to evaluate the prevalence of thyroid disease, atopic dermatitis and allergic diseases in children with alopecia areata and compare the results with healthy individuals. METHODS This case-control study was con...
متن کاملFactors Associated with Severity of Alopecia Areata
BACKGROUND Alopecia areata is the most common cause of localized, nonscarring alopecia. Unfortunately, there are few data regarding clinical features and epidemiology of alopecia areata in Korean patients, and its clinical course and treatment response rates are unpredictable. OBJECTIVE This study strived to investigate the differences in clinical profiles according to disease severity and to...
متن کاملDupilumab, A Monoclonal Antibody for Atopic Dermatitis: A Review of Current Literature.
Atopic dermatitis results when aberrant barrier function and immune activation occur within the skin. Standard therapies for atopic dermatitis have fallen short, prompting efforts to discover novel therapeutics for this disease. Of these, dupilumab, a fully human monoclonal antibody that inhibits the actions of both IL-4 and IL-13, has shown the greatest promise. Clinical trials of systemic dup...
متن کاملA case-control study on family dysfunction in patients with alopecia areata, psoriasis and atopic dermatitis.
Family history can provide important information about a patient's psychological status, and thus their disease risk. A multicentric case-control study on family dysfunction was performed on 59 patients with psoriasis (63.7%), atopic dermatitis (11.9%) or alopecia areata (25.4%), and 47 patients with minor skin problems (controls), all attending a dermatological clinic or a psychodermatological...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 4 شماره
صفحات -
تاریخ انتشار 2018